linjc16/ctgov huggingface dataset:
Clinical and Radiological Prognostic Factors of Acute Necrotizing Encephalopathy in Sohag University Hospital

Study Overview
=================
Brief Summary
-----------------
Acute necrotizing encephalopathy of childhood (ANEC) is a fulminant type of encephalopathy. Most reported cases occur in Asian children with the highest prevalence among patients between the age of 6 and 18 months. The most common clinical presentations are fever, rapid alteration in the level of consciousness, and seizures, in addition to characteristic findings in brain imaging that include, but are not limited to, bilateral thalamic lesions with supra and infra-tentorial lesions of variable dimensions. The diagnosis of ANEC was determined by specific diagnostic criteria as described by Mizuguchi [1] which consist of Encephalopathy preceded by viral febrile illness with rapid deterioration in the level of consciousness and convulsions. Absent cerebrospinal fluid (CSF) pleocytosis. Symmetric multifocal brain lesions. Elevation in serum aminotransferase levels. Exclusion of similar diseases. The ANE severity score was used to assess the severity of illness after admission for shock (3 points), brainstem lesions (2 points), age >4 years (2 points), platelet (PLT) count < 100,000 (1 point), and elevated CSF protein (1 point) was observed. [3] A total score of 9

Official Title
-----------------
Clinical and Radiological Prognostic Factors of Acute Necrotizing Encephalopathy in Sohag University Hospital

Conditions
-----------------
Acute Necrotizing Encephalopathy

Intervention / Treatment
-----------------
* Other: Basic Laboratory investigations , Cerebrospinal fluid analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Children aged from 2months up to 12 years admitted to the pediatric emergency department or pediatric ICU presented with Acute encephalopathy & meet diagnostic criteria of acute necrotizing encephalopathy or come for follow up in our outpatient clinic. Exclusion Criteria: Children known to have metabolic disease. Children who have picture of CNS infection & confirmed by CSF analysis.

Ages Eligible for Study
-----------------
Minimum Age: 2 Months
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Basic Laboratory investigations , Cerebrospinal fluid analysis|to detect severity and prognostic factors of Acute Necrotizing Encephalopathy|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Acute necrotizing encephalitis severity score | Clinical and Radiological Prognostic Factors of Acute Necrotizing Encephalopathy in Sohag University Hospital | one year |
A Modified Calculation Formula for Meibomian Gland Grading

Study Overview
=================
Brief Summary
-----------------
The meibomian gland (MG) is a modified sebaceous gland located in the upper and lower eyelids. The grades of MG loss (i.e. meiboscore) is calculated as the ratio between the area of the MGs and the eyelids, and this calculation is based on the two-dimensional digital infrared images.In the current formula, the area of the eyelid is the denominator. However, because the eyelids need to be flipped over for the examination and evaluation, and there may be interobserver variability in the measurement of the area of the eyelids. Aging and involutional eyelid disorders, such as ptosis, ectropion, and entropion, may lead to laxity or deformation of eyelids, and impact the shape and area of eyelid area consequently.These factors could cause inaccuracy in current evaluation method, and impact the grading and evaluation of treatment efficacy of MGD, especially in self-controlled studies, such as in clinical trials. In this study, the investigators propose to use a modified calculation formula for the grading of MGs. The investigators could measure the white to white (WTW) distance of cornea, and then calculate the area of cornea (i.e. corneal base area) accordingly.Unlike the eyelid, the WTW distance does not change significantly during aging or between sexes.Thus, the investigators hypothesize that using the corneal base area as the new denominator in the formula for the grading of MG loss is a better way comparing with the conventional method.

Official Title
-----------------
A Modified Calculation Formula for Meibomian Gland Grading

Conditions
-----------------
Meibomian Gland Dysfunction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: people aged 18 to 80 Exclusion Criteria: Exclusion criteria included contact lens wearer, history of eye surgeries, systemic health conditions affecting ocular health and those who were unable to cooperate with examinations.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| previous calculation formula<br> | |
| modified calculation formula<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the area of the MGs and the whole eyelids |  | Baseline (Once a subject has enrolled in research) | 
| the WTW distance of the cornea |  | Baseline (Once a subject has enrolled in research) |
Incidence of Colorectal Cancer in Southwest China: Based on SCC Database

Study Overview
=================
Brief Summary
-----------------
To evaluate recent trends in CRC incidence, treatment, and survival in the Southwest China.

Detailed Description
-----------------
The epidemiological feature of colorectal cancer (CRC) showed different trends among countries. Studying the epidemiological and management characteristics between China and the US has important implications for understanding the current status of cancer occurrence, treatment and survival. we established the Southwest China Colorectal (SCC) database, aiming to provide reference information on the diagnosis and management of CRC in China.

Official Title
-----------------
Incidence of Colorectal Cancer in Southwest China: Based on SCC Database

Conditions
-----------------
Colorectal Cancer

Intervention / Treatment
-----------------
* Other: treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of colorectal cancer; Received treatment in medical institutions; Regular follow-up after the diagnosis. Exclusion Criteria: Patients who lost to follow-up
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CRC cases<br> | Other: treatment<br>* the actual treatment CRC patients have reveived<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival | Overall survival (OS) untile the end of follow up | From inclusion until date of death from any cause, or untile the 2023-10-31 |
Comparison of Different Types of Prosthetic Foott

Study Overview
=================
Brief Summary
-----------------
The main purpose of this study is to determine the experiences of patients with different types of prostetic feet (carbon, hydraulic or microprocessor controlled).

Detailed Description
-----------------
One of the main goals in the rehabilitation of amputees is to provide optimal and natural ambulation. For this purpose, suitable socket-suspension type, appropriate knee joint and foot should be prescribed. In the selection of feet, the age, occupation, characteristics of the geographical region, mental status and activity level should be considered. In addition, the previous prosthesis experience of the people should definitely be taken into account during prosthesis prescribing.The main purpose of this study is to determine the experiences of patients with different types of prostetic feet (carbon, hydraulic or microprocessor controlled).

Official Title
-----------------
Comparison of Different Types of Prosthetic Foot: Patient Perspective

Conditions
-----------------
the Previous Prosthetic Foot Experience of Patients With Amputation

Intervention / Treatment
-----------------
* Other: Prosthetic foot questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged between 18-65 years Lower limb amputation Having used at least 2 different foot types (carbon, hydrolic, microprocessor-controlled) Exclusion Criteria: Having used the single type of foot until now Presence of neurological, cardiovascular, and pulmonary disease that may affect walking performance

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients<br>the previous prosthesis experience | Other: Prosthetic foot questionnaire<br>* Prosthetic foot related questions will be asked to the patients<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Qestion 1 | Walking on the straight road | through study completion, an average of one and a half months | 
| Qestion 2 | Walking on uneven terrain | through study completion, an average of one and a half months |
Feasibility of Integrated Care of Depression in Primary Care Pathways

Study Overview
=================
Brief Summary
-----------------
This protocol is a feasibility study of an integrated primary care pathway for patients suffering from difficult-to-treat depression. 50 patients will be recruited and followed for two years.

Official Title
-----------------
Evaluation de Soins Primaires Intégrés en Psychiatrie

Conditions
-----------------
Depressive Disorder

Intervention / Treatment
-----------------
* Other: Integrated care


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 18-65 years Good understanding of french language Major depressive disorder based on DSM-V criteria MADRS > 19 FAilure of two antidepressants during 6wks at standard minimal dose Exclusion Criteria: Pregnancy or lactating People under tutelage bipolar disorder no health insurance neurological disorders contra-indication to physical activity high suicidal risk first degree history of bipolar disorder, schizophrenia, autism spectrum disorder

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Integrated care<br> | Other: Integrated care<br>* Psychiatric follow-up, cognitive behavioral therapy, physical exercise, psychoeducation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients completing the study per-protocol |  | 3 years |
Use of Belatacept to Delay Tacrolimus Initiation in Kidney Transplant Patients With Delayed Graft Function

Study Overview
=================
Brief Summary
-----------------
Evaluate the impact of one dose of belatacept in patients with Delayed Graft Function(DGF) on their time to renal recovery and corresponding rates of patient and graft survival, rejection, and incidence of BK virus(BKV), Epstein-Barr Virus(EBV) and/or cytomegalovirus (CMV) infections.

Detailed Description
-----------------
Evaluate the impact of one dose of belatacept in patients with DGF on their time to renal recovery and corresponding rates of patient and graft survival, rejection, and incidence of BK virus, EBV and/or cytomegalovirus (CMV) infections. At Methodist Dallas Medical Center(MDMC), while providers may choose to initiate belatacept to delay tacrolimus initiation, the impact of this practice on time to renal recovery has not been evaluated. The purpose of this study is to determine if administering belatacept to delay initiation of tacrolimus shortens time to renal recovery in DGF patients

Official Title
-----------------
Use of Belatacept to Delay Tacrolimus Initiation in Kidney Transplant Patients With Delayed Graft Function

Conditions
-----------------
Use of Belatacept in Kidney Transplant Patients

Intervention / Treatment
-----------------
* Behavioral: impact of administering one dose of belatacept on Estimated Glomerular Filtration Rate(eGFR)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥18 years Received living or deceased donor kidney transplant during study period Documented DGF Exclusion Criteria: Multiple organ transplant Recipients with acute rejection present on first biopsy evaluation before first belatacept dose Recipients with a first dose of belatacept after index discharge or tacrolimus initiation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: impact of administering one dose of belatacept on Estimated Glomerular Filtration Rate(eGFR)|Evaluate the clinical impact of administering one dose of belatacept on eGFR at one-year post-transplant, patient and graft survival outcomes, graft rejection, and incidences of BK virus, EBV and CMV infections.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to renal recovery | weeks 1-4, and months 3, 6, 9 and 12) to capture potential short- and long-term effects on renal function. | 1 year | 
| post-transplant outcome | Patient survival o Graft survival Graft rejection | 1 year |
Computer-Assisted Hair Restoration Study Using ARTAS System

Study Overview
=================
Brief Summary
-----------------
Prospective, multi-center, up to 4 investigational centers evaluating the performance of the ARTAS System in Hair Restoration Procedures.

Official Title
-----------------
Computer-Assisted Hair Restoration Study Using ARTAS System

Conditions
-----------------
Androgenic Alopecia

Intervention / Treatment
-----------------
* Device: Hair restoration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject is male with clinical diagnosis of androgenetic alopecia with Norwood-Hamilton grade of III-VI Subject is 20 to 70 years old Subject agrees to cut hair short (< 1 mm) on the scalp in the designated study areas for harvesting and implantation Subject is able to understand and provide written consent Subject consents to post-operative follow-up per protocol Exclusion Criteria: Subject has prior history of scalp reduction surgery(s) in the past six months Subject has bleeding diathesis Subject has active use of anti-coagulation medication Subject has any other condition that, in the opinion of the investigator, makes the subject inappropriate to take part in this study

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: All subjects<br>The Study Treatment will involve follicular hair unit harvest, recipient site making, and implantation. | Device: Hair restoration<br>* The Study Treatment will involve follicular hair unit harvest, recipient site making, and implantation.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Hair Density from pre to 12 months post-treatment in robotic vs manual implantation |  | 1 year post-treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of follicles successfully harvested by Robot |  | 1 year post-treatment |
A Study of Factors Influencing Recurrence After Thermal Ablation of Papillary Thyroid Carcinoma

Study Overview
=================
Brief Summary
-----------------
A prospective cohort of papillary thyroid carcinoma(PTC), patients who received thermal ablation in our hospital since February 2023 was established as the study object. Preoperative and postoperative demographic data, ultrasonography, other relevant laboratory tests, and thyroid disease-related scales such as fatigue, depression, and stress were collected. The influencing factors of PTC recurrence were analyzed.

Official Title
-----------------
A Study of Factors Influencing Recurrence After Thermal Ablation of Papillary Thyroid Carcinoma

Conditions
-----------------
Papillary Thyroid Carcinoma, Thermal Ablation

Intervention / Treatment
-----------------
* Other: No Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ①≥18 years old; ② Obtain informed consent; ③ Ultrasonography showed that malignant nodules were single, the maximum diameter of nodules was ≤1cm and the distance from the capsule was ≥2mm. ④ no lymph node metastasis or other extra-glandular metastasis in the neck; ⑤ PTC was confirmed by fine needle puncture pathology; ⑥ Patients who do not meet Article 3, who still strongly request thermal ablation while fully informing the patient of the risk of recurrence, and who have been clinically assessed to be technically capable of thermal ablation Exclusion Criteria:① Pregnant or lactating patients; ② Patients with other malignant tumors and not suitable for ablation by clinical evaluation; ③ Patients who cannot tolerate surgery; ④ Patients with cognitive impairment and other conditions who cannot accurately fill in thyroid-related questionnaires.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention<br> | Other: No Intervention<br>* No Intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the recurrence of PTC | the recurrence of PTC during follow-up | 1 to 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Papillary Thyroid Carcinoma, cohort, Thermal Ablation, Recurrence
Monoferric for Prenatal Iron Deficiency

Study Overview
=================
Brief Summary
-----------------
A prospective observational study of pregnant women with iron deficiency anemia and oral iron intolerance or advanced gestational age.

Detailed Description
-----------------
Intravenous therapy (IV) Monoferric (ferric derisomaltose), is a single-dose, rapid infusion formulation that has the potential to reduce both time and cost barriers, though its efficacy and safety in pregnant women has not been well studied. Thus, we propose to study the safety and efficacy of single dose, monoferric 1,000 mg IV in a cohort of pregnant participants with iron deficiency.

Official Title
-----------------
Monoferric for Prenatal Iron Deficiency

Conditions
-----------------
Obstetric Labor Complications

Intervention / Treatment
-----------------
* Drug: Ferric derisomaltose


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants 18 years of age or older between 14 to 42 weeks gestation who are deemed appropriate for IV iron by their treating provider as part of their standard of care treatment. Iron deficiency anemia, defined as second or third trimester (14 weeks or more) hemoglobin less than or equal to 10.5 g/dL or less than or equal to11 g/dL, respectively, and ferritin less than 50 μg/L Experience intolerance to oral iron or are greater than 28 weeks gestation Willing to participate in the study Exclusion Criteria: Known infectious, inflammatory, or malignant conditions that may confound iron repletion and outcome analysis Prior IV iron intolerance or hypersensitivity reaction

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ferric derisomaltose<br> | Drug: Ferric derisomaltose<br>* Participants between the gestational ages of 14 to 42 weeks with iron deficiency will receive IV Ferric derisomaltose at a routine prenatal visit.<br>* Other names: Monoferric;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The proportion of participants who experienced a resolution of iron deficiency anemia | The proportion of participants who experienced a resolution of iron deficiency anemia, defined as a 1 g/dL increase in Hgb at a follow up assessment at 6 weeks postpartum following IV Monoferric administration | From enrollment to 6 weeks post partum |